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Junctional epidermolysis bullosa is a heritable, hetero-
geneous blistering skin disease with mechanically
induced dermal–epidermal separation, mild skin
atrophy, nail dystrophy, and alopecia. Four unrelated
junctional epidermolysis bullosa families with different
phenotypes were investigated here and four novel
mutations associated with the disease were identified.
Patients 1, 2, and 3 had generalized atrophic benign
epidermolysis bullosa, with nonscarring blistering and
varying degree of alopecia. Patient 4 had the localisata
variant of junctional epidermolysis bullosa, with pre-
dominantly acral blistering and normal hair. All patients
had mutations in the COL17A1 gene encoding collagen
XVII, a hemidesmosomal transmembrane protein.
Patients 1 and 2 carried homozygous deletions 520delAG
and 2965delG, respectively. Patient 3 was compound
Collagen XVII, or 180 kDa bullous pemphigoid antigen,is a structural hemidesmosome component (Nishizawaet al, 1993). It is a type II transmembrane molecule witha globular cytoplasmic domain and a large collagenousextracellular domain (Giudice et al, 1992; Li et al, 1993;
Hirako et al, 1996; Gatalica et al, 1997). As a transmembrane component,
it presumably maintains the linkage between intracellular and extracellu-
lar structures and anchors the keratinocytes to the basement membrane
(Borradori et al, 1997). This concept is supported by pathologic
conditions. In bullous autoimmune diseases collagen XVII autoanti-
bodies are associated with diminished epidermal–dermal cohesion (Liu
et al, 1993; Balding et al, 1996; Zillikens et al, 1997), and in certain
junctional epidermolysis bullosa (JEB) subtypes expression of collagen
XVII is abnormal (Jonkman et al, 1995).
JEB refers to a group of heritable disorders with features of skin
fragility, ultrastructurally abnormal hemidesmosomes (McMillan et al,
1998), and separation of the epidermis from the basement membrane.
JEB includes several subtypes, varying from lethal Herlitz JEB to a
mild acral subtype (Gedde-Dahl and Anton-Lamprecht, 1990;
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heterozygous for a missense and a deletion mutation
(G539E and 2666delTT), and patient 4 was heterozygous
for a known mutation R1226X. The deletions led to
premature termination codons and to drastically reduced
collagen XVII mRNA and protein levels, consistent
with the absence of the collagen in generalized atrophic
benign epidermolysis bullosa skin. The missense
mutation G539E allowed synthesis of immunoreactive
collagen XVII in keratinocytes, but prevented its
secretion, thus causing lack of the protein in the skin.
The data suggest that different COL17A1 mutations
and their combinations can result in a spectrum of
biologic and clinical phenotypes of not only generalized
atrophic benign epidermolysis bullosa, but also localized
junctional epidermolysis bullosa. Key words: basement
membrane/bullous pemphigoid antigen/collagen/hemidesmo-
some. J Invest Dermatol 111:528–533, 1998
Bruckner-Tuderman, 1993). Generalized atrophic benign epidermolysis
bullosa (GABEB) represents a subtype with generalized blistering, skin
atrophy, alopecia of the scalp, scarce eyelashes, eyebrows, and secondary
sexual hair, as well as nail dystrophy and dental anomalies (Hashimoto
et al, 1976; Hintner and Wolff, 1982). A dozen or so COL17A1 gene
mutations have been disclosed in GABEB (McGrath et al, 1995, 1996a,
b; Darling et al, 1997, 1998a, b; Chavanas et al, 1997; Gatalica et al,
1997; Jonkman et al, 1997; Schumann et al, 1997) and one mutation
in localized acral JEB (Schumann et al, 1997). Most of these were
homozygous or heterozygous mutations leading to a premature termina-
tion codon (PTC) and absence of collagen XVII in the skin. In this
study, we identified novel COL17A1 mutations in JEB. Three deletions
resulted in PTC, whereas two heterozygous point mutations led to
different biologic and clinical phenotypes.
MATERIALS AND METHODS
Patients
Patient 1 The proband, a 75 y old German male, was the fifth child of healthy
nonconsanguineous parents. He never had had children and had no living
relatives. Two of his older brothers had had similar skin blistering, and two
other brothers had died in infancy of ‘‘lethal epidermolysis bullosa.’’ The
proband had generalized blisters since birth, and affection of the face and the
oral mucosa was common. The bullae healed without scars, but with some
atrophy and hyperpigmentation. Dystrophy of all nails and dental problems,
anamnestically caries, developed in childhood. The proband never had axillary
or genital hair, but the scalp hair remained normal. At the age of 75, he had
gray hair with male pattern androgenetic alopecia. Thus, he presented with
characteristic features of GABEB, except for the normal scalp hair. Electron
microscopy showed junctional blistering and hypoplastic hemidesmosomes.
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Patient 2 The proband, a 6 y old Turkish female, is an offspring of a
consanguineous union. No other family member had a similar skin disorder.
The proband had fragility of the skin and the mucous membranes since birth,
with the extremities and the face being most often affected. The blisters healed
without scarring, but were accompanied by dystrophy and loss of most nails.
Affection of the scalp led to sparse hair and occipital alopecia. The teeth
were normal. Electron microscopy showed junctional blistering and severely
hypoplastic hemidesmosomes.
Patient 3 The proband, a 12 y old female, is the younger child of nonconsan-
guineous Polish parents. The family history was negative for skin diseases. At
birth, the proband presented with blisters of the arms and legs. Later, generalized
blistering continued, with the extremities, head, face, and oral mucosa being
strongly affected. Healing took place without scars, but with skin atrophy and
hyperpigmentation. The teeth showed fragile enamel and tendency to dental
caries. Nail dystrophy and patchy alopecia of the scalp developed early, leading
to a total loss of hair by the age of 12 y. Thus, the proband exhibited the
GABEB phenotype with extensive alopecia.
Patient 4 The 34 y old male proband is an offspring of healthy nonconsanguin-
eous Polish parents. No other family member had a related skin disorder. The
proband had nonscarring blistering since birth, initially generalized but later
localized to the distal extremities. Along the course of the disease, a slight
hyperpigmentation of the skin and dystrophy of the toe nails developed. The
patient had no dental anomalies, yet tendency to dental caries. Remarkably,
the scalp and body hair were completely normal. Based on the clinical
presentation, he was initially thought to have epidermolysis bullosa simplex,
until antigen mapping revealed junctional splitting and abnormal expression of
collagen XVII in the skin.
Mutation detection Genomic DNA was isolated from peripheral blood
using the Easy-DNA Kit (Invitrogen, Leek, The Netherlands). Polymerase
chain reaction (PCR) amplification of COL17A1 exons 8, 18, 37, 43, and 51
was performed as described by Gatalica et al (1997; GenBank No. M91669).
The size of the PCR product of exon 8 was 219 bp; exon 18, 384 bp; exon
37, 261 bp; exon 43, 340 bp; and exon 51, 374 bp. Heteroduplex analysis was
according to Ganguly et al (1993). Heteroduplex forming PCR products were
sequenced by an automated sequencer (Genome Express, Grenoble, France).
Northern blotting Northern blotting with keratinocyte mRNA isolated
with Oligotex Direct mRNA Minikit (QIAGEN, Hilden, Germany) was
performed essentially as described (Schumann et al, 1997). For hybridization, a
collagen XVII cDNA (Gatalica et al, 1997) was labeled with digoxigenin using
the digoxigenin DNA Labeling Kit (Boehringer, Mannheim, Germany). The
detection was with alkaline phosphatase-labeled digoxigenin-antibodies and
CDP-Star substrate (Boehringer).
Keratinocyte cultures Control and JEB keratinocytes were obtained by
trypsinization of skin biopsies and cultured in SFM medium (Gibco, Grand
Island, NY). Prior to the assays, the cells were grown for 48 h in the presence
of 50 µg ascorbic acid per ml to allow for hydroxylation of prolyl residues and
correct folding of the collagen (Prockop and Kivirikko, 1995).
Antibodies and immunodetection of proteins The monoclonal antibodies
1A8C to the intra- and 1D1 to the extracellular domain of collagen XVII
(Kitajima et al, 1992; Nishizawa et al, 1993) were used for immunofluorescence
(IF) staining of skin cryosections or cultured keratinocytes. A pemphigoid
autoantiserum recognizing the NC16a domain of collagen XVII was used for
immunoblotting (Schumann et al, 1997). For antigen mapping (Hintner et al,
1981) the following antibodies were employed: cytokeratins (Dako, Hamburg,
Germany), BP230 (a high titer autoantiserum), α6 and β4 integrins (Gibco Life
Technologies, Eggenstein, Germany), collagen IV (Dako), laminin 5 (a kind
gift from Dr. R. Burgeson, CBRC, Harvard Medical School, Cambridge, MA),
and collagen VII (Bruckner-Tuderman et al, 1995). For immunoblotting,
keratinocytes were extracted with a buffer containing 0.1 M NaCl, 20 mM
Tris-HCl, pH 7.4, 1% NP-40, and proteinase inhibitors (Sonnenberg et al,
1991; Schumann et al, 1997), and the proteins were separated on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis with 4.5–15% polyacryl-
amide gradients.
RESULTS
Identification and verification of mutations Mutation screening
included PCR amplification of COL17A1 exons directly from genomic
DNA (Gatalica et al, 1997). In family 1, exon 8 was affected; in family
2, exon 43; in family 3; exons 18 and 37; and in family 4, exon 51.
Heteroduplex formation of the patients’ DNA mixed with control
DNA indicated homozygosity of patients 1 and 2, and heteroduplex
formation by the patient’s DNA alone indicated heterozygosity of
patients 3 and 4 (Fig 1). Patient 1 was homozygous for a 520delAG
deletion that led to a frameshift and an adjacent PTC. Patient 2 was
homozygous for the deletion 2965delG that caused a PTC 334 bp
downstream. Verification of this mutation by BstNI endonuclease
digestion showed that each parent was heterozygous. Patient 3 was
compound heterozygous for a 1721G→A transition in exon 18 and
for a 2666delTT deletion in exon 37 that led to a PTC 328 bp
downstream. The G→A transition caused a Glu for Gly substitution
at amino acid position 539 and was designated G539E. Verification
by AluI endonuclease digestion demonstrated that the mother was
heterozygous. In contrast, the mutation was not found in 150 normal
chromosomes, indicating that it is not a neutral polymorphism. The
father was heterozygous for 2666delTT, but the unaffected brother
carried neither mutation. Patient 4 was compound heterozygous for a
3781C→T transition designated R1226X (McGrath et al, 1995; Jonk-
man et al, 1997; Schumann et al, 1997). Verification with TaqI digestion
demonstrated that his father and sister were heterozygous for this
mutation. Despite PCR amplification of all 56 COL17A1 exons,
multiple heteroduplex analyses and extensive didesoxynucleotide
sequencing failed to reveal the maternal mutation of this proband.
Expression of COL17A1 mRNA Northern blots with normal
keratinocyte mRNA showed a strong 6 kb collagen XVII mRNA
signal. In contrast, mRNA from patient 1’s keratinocytes produced a
very weak signal, suggesting nonsense-mediated mRNA decay in these
cells (Fig 2). Sufficient mRNA from patients 2, 3, and 4 was not
available for the analysis.
Collagen XVII in the skin IF staining with antibodies 1A8C and
1D1 was negative in the skin of patients 1, 2, and 3 (Fig 3a, c, e).
1A8C produced a weak staining within basal keratinocytes of patient 4
(Fig 3g). In spontaneously blistered skin of all patients, the antibodies
to cytokeratins, BP230, and α6 and β4 integrins stained the blister
roof, and the antibodies to laminin 5, collagens IV, and VII stained
the blister floor (Fig 3b, d, f, h). This staining pattern thus confirmed
junctional tissue separation in all four patients.
Synthesis of collagen XVII in vitro IF staining of control ker-
atinocytes with collagen XVII antibodies showed a positive reaction
in the rough endoplasmatic reticulum, and in the cell periphery
corresponding to the transmembrane location of collagen XVII (Fig 4a).
In contrast, the staining of patient 1’s keratinocytes was negative
(Fig 4b). Staining of patient 3’s keratinocytes with the antibody to the
intracellular (Fig 4c) and extracellular (Fig 4d) domain of collagen
XVII revealed a positive intracellular IF signal. No membrane-bound
staining was observed in these cells, indicating intracellular accumulation
and degradation of the mutant polypeptides. Keratinocytes of patients
2 and 4 were not available for the studies.
Immunoblotting results were consistent with the IF staining.
Keratinocytes were cultured in the presence of ascorbic acid to
stabilize newly synthesized collagens (Prockop and Kivirikko, 1995)
and immunoblotted with polyclonal collagen XVII antibodies. The
180 kDa α1(XVII)-chain was found in controls, however, and not in
extracts of patients 1, 3, and 4 (Fig 4e). This observation indicates that
the nascent mutant α1(XVII) chains in the cells of patient 3 (see
Fig 4c, d) were degraded intracellularly by default mechanisms.
Keratinocytes from patient 2 were not available for these studies.
DISCUSSION
Here we report novel COL17A1 gene mutations associated with JEB.
All but one (Schumann et al, 1997) of the previously described
COL17A1 defects (McGrath et al, 1995, 1996a, b; Darling et al, 1997,
1998a, b; Chavanas et al, 1997; Gatalica et al, 1997; Jonkman et al, 1997)
were associated with the GABEB phenotype, including generalized
blistering, skin atrophy, nail dystrophy, and, the clinical hallmark of
this JEB subtype, extensive nonscarring alopecia. Interestingly, the
three GABEB patients of this study showed a variable degree of
alopecia. Patient 1, now 75 y old, still had normal scalp hair. The 6 y
old patient 2 exhibited an intermediate, and patient 3 a drastic
phenotype with complete baldness at the age of 12 y.
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Figure 1. Pedigrees of the probands and mutations in the COL17A1 gene. Pedigrees demonstrate recessive inheritance of the mutations. (A) family 1; (B)
family 2; (C) family 3; (D) family 4. (A) Heteroduplex bands were detected on CSGE gels of PCR product spanning exon 8 (middle panel). Control DNA (lane 1)
and the patient’s DNA (lane 2) showed homoduplex bands when tested alone. The faster migration of the patient’s homoduplex band suggested a deletion in this
fragment. Heteroduplex bands were seen in mixed samples of the patient’s and control DNA (lane 3). Didesoxynucleotide sequencing of the patient’s DNA revealed
a homozygous 2 bp deletion in exon 8, designated 520delAG (right panel), whereas the deletion was absent from a control (left panel). (B) CSGE analysis of PCR
product spanning exon 43 (middle panel) revealed a homoduplex band in control DNA (lane 1) and the patient’s DNA (lane 2), but heteroduplex bands when the
samples were mixed with each other (lane 3). Direct didesoxynucleotide sequencing of the patients’ PCR products revealed a homozygous 1 bp deletion of
nucleotide G in exon 43, designated 2965delG (right panel), which was absent from a control (left panel). (C) CSGE analysis of the PCR products spanning exons
18 and 37 revealed heteroduplex bands with the patient’s DNA, indicating compound heterozygosity of the proband (middle panels). The upper middle panel shows
CSGE analysis of PCR product spanning exon 37 (paternal mutation); control DNA (lane 1) showed a homoduplex band and the patient’s DNA (lane 2) homo-
and heteroduplex bands. The lower homoduplex band (asterisk) was excised, eluted, reamplified, and subjected to didesoxynucleotide sequencing that revealed a
heterozygous 2 bp deletion in exon 37, designated 2666delTT (right panel), which was absent from a control (left panel). This heterozygous deletion was also found
in the father’s DNA. The lower middle panel shows CSGE analysis of PCR product spanning exon 18 (maternal mutation); control DNA (lane 1) showed a
homoduplex band and the patient’s DNA (lane 2) heteroduplex bands. Direct didesoxynucleotide sequencing of the patients’ PCR products revealed a heterozygous
1721G→A transition in exon 18, designated G539E (right panel), which was absent from a control (left panel). This heterozygous mutation was also found in the
mother’s DNA. In the pedigree, the black areas indicate the paternal and the dotted areas the maternal allele. (D) Identification of the paternal mutation. CSGE
analysis of PCR product spanning exon 51 (middle panel) revealed a homoduplex band in control (lane 1) and the mother’s DNA (lane 4). In contrast, heteroduplex
bands were seen with the patient’s (lane 2), the father’s (lane 3), and the sister’s DNA (lane 5). Direct didesoxynucleotide sequencing of the patient’s PCR products
revealed a heterozygous 3781C→T transition in exon 51, designated R1226X (right panel). The mutation was also found in the unaffected father and sister, but
not in a control or the mother (left panel). Extensive mutation screening did not reveal other changes in the COL17A1 gene and therefore the maternal mutation
remained elusive.
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Figure 2. Northern blotting of collagen XVII mRNA from normal and
GABEB keratinocytes. A strong signal of the 6 kb collagen XVII mRNA
was found in control keratinocytes (Co). In contrast, collagen XVII mRNA
isolated from the patient 1’s keratinocytes (Pat 1) produced a very weak signal,
suggesting nonsense-mediated mRNA decay in these cells. The panels were
intentionally overexposed to demonstrate the presence of the weak collagen
XVII mRNA band in the patient’s cells. A digoxigenin-labeled GAPDH cDNA
was used as a reference probe to correct for differences in RNA loading.
Patients 1 and 2 were homozygous for a PTC and lacked collagen
XVII in the skin. The biologic phenotype was in concert with the
observation that most mutations resulting in PTC cause nonsense-
mediated mRNA decay and lack of the synthesis of the corresponding
protein (Cui et al, 1995). Patient 3 was compound heterozygous for a
missense (G539E) and a nonsense (2666delTT) mutation. Unexpec-
tedly, this combination also led to lack of collagen XVII in the skin.
When cultured, the proband’s keratinocytes synthesized and retained
intracellularly immunoreactive polypeptides, but no deposition of
collagen XVII at the plasma membrane was observed. The nonsense
mutation is likely to result in accelerated mRNA decay (Darling et al,
1998b) and therefore the proband can be regarded as hemizygous for
the G539E substitution at the mRNA and protein level. The Gly
substitution by Glu in the NC16a domain seems to destabilize the
nascent polypeptides and cause retention of mutant molecules in
the cell and subsequent degradation through default pathways, a
phenomenon coined ‘‘protein suicide’’ of mutant trimeric collagens
(Prockop and Kivirikko, 1995). The mutant α1(XVII) chains were
only seen by IF in keratinocytes with a high level of expression in vitro,
but they were not sufficiently stable to resist the extraction and
immunoblotting procedures. Neither were they visible by IF in the
epidermis where the rate of synthesis is low. One possible explanation
for the extensive intracellular retention and degradation is that the
G539E substitution occurred within a functionally essential sequence
of the NC16a domain, adjacent to the transmembrane domain. This
segment contains the immunodominant epitopes in autoimmune
blistering disorders (Zillikens et al, 1997), and binding of the autoanti-
bodies to the epitopes has been shown to lead to perturbation of
collagen XVII functions (Liu et al, 1993).
Two other missense mutations in COL17A1 have been reported.
In a compound heterozygous GABEB patient with a less severe
phenotype, McGrath et al (1996b) disclosed a G627V substitution
within the COL15 domain, in combination with an internal duplication
that led to a PTC. Similar to our patient 3, the proband lacked collagen
XVII in the skin. The authors regarded G627V as dominant, because
the proband’s offspring who had inherited this mutation presented
with dental anomalies, but not with skin fragility. In the present family
3, the mother heterozygous for G539E was phenotypically normal and
Figure 3. IF staining of the patients’ skin with antibodies to cutaneous
basement membrane components. The biopsies and antibodies used were:
(a) patient 1, 1A8C; (b) patient 1, laminin 5; (c) patient 2, 1A8C; (d) patient 2,
integrin α6; (e) patient 3, 1A8C; (f) patient 3, collagen VII; (g) patient 4, 1A8C;
(h) patient 4, collagen VII. In (g), a weak reactivity with the antibody 1A8C
was observed in the basal keratinocytes of the detached epidermis. The stainings
with antibodies to other basement membrane proteins were normal. In blistered
skin of patient 2, antibodies to integrin α6 localized to the blister roof (d).
Antibodies to collagen VII stained the blister base in separated skin of patients
3 (f) and 4 (h). The staining patterns were consistent with junctional blistering.
Scale bar: 40 µm.
without dental problems. Interestingly, both glycine substitutions
G627V and G539E in the NC16a domain were associated with
GABEB phenotypes of different severity. In contrast, a homozygous
R1303Q substitution at the C-terminus of collagen XVII led to JEB
localisata (Schumann et al, 1997). This mutation did not influence
secretion of collagen XVII, but possibly created a novel transglutaminase
cross-linking site, because large collagen XVII aggregates were found
in the epidermis.
Our patient 4 presented with JEB localisata and normal hair, despite
a COL17A1 nonsense mutation. He was heterozygous for R1226X
previously reported in GABEB families from the U.K., Holland, and
Germany (McGrath et al, 1995; Jonkman et al, 1997; Schumann et al,
1997). This mutation may represent a mutational hot spot similar to
one in the LAMB3 gene associated with JEB Herlitz (Kivirikko et al,
1996). Alternatively, the mutation may have a common founder in
Central Europe, as observed for the COL17A1 mutation 4003delTC
that represents a common ancestral allele in Austrian GABEB families
(Darling et al, 1998a).
The phenotypic heterogeneity of COL17A1 defects is likely to be
greater than previously expected. Mutation combinations can lead to
different JEB phenotypes, and not all nonsense mutations are associated
with GABEB and extensive alopecia, but can result in milder clinical
presentation. Mutation screening and biologic and protein chemical
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Figure 4. Immunodetection of collagen XVII in keratinocytes in vitro.
(a–d) IF staining of GABEB keratinocytes with domain-specific antibodies
to collagen XVII. In control cells, the antibody 1D1 to the extracellular
domain showed a positive reaction in the rough endoplasmatic reticulum
and in the cell periphery, corresponding to the transmembrane localization
(a). The antibody produced a negative reaction in the keratinocytes of
patient 1 (b). Staining of keratinocytes of patient 3 with the antibody 1A8C
to the intracellular domain revealed a positive diffuse intracellular fluorescence
(c), and with the antibody 1D1 to the extracellular domain a diffuse weak
reaction (d). Scale bar: 10 µm. (e) Immunoblotting of keratinocyte extracts
with polyclonal antibodies to the NC16a domain. Normal controls contained
the 180 kDa α1(XVII)-chain (lanes 1, 3, 5). In contrast, cell extracts of
patient 1 (lane 2), patient 3 (lane 4), and patient 4 (lane 6) lacked the band,
indicating absence of stable collagen XVII in these cells. The 65 kDa band
in lane 6 was occasionally seen with the human autoantiserum used, but its
identity has not been characterized. The migration positions of molecular
weight markers are indicated on the right.
analyses of further JEB families will reveal the genotype-phenotype
correlations and lay a basis for novel gene therapeutic approaches
for JEB.
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